Mucosal Melanoma
Cross-source consensus on Mucosal Melanoma from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Risks & contraindications
Comparisons
Evidence quality
Where it comes from
Highlighted claims
- Mucosal melanoma is biologically distinct and arises from mucosal sites including the sinonasal and gastrointestinal tracts. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
- Mucosal melanoma has worse prognosis than cutaneous melanoma and a high relapse risk after surgery. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
- A nationwide cohort reported poor long-term survival for mucosal melanoma. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
- Mucosal melanoma represents a larger share of melanoma cases in Asian populations than in Western populations. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
- Surgery is the main treatment for localised mucosal melanoma, but optimal adjuvant therapy remains unsettled. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial